RBC Capital analyst Douglas Miehm raised the firm’s price target on Knight Therapeutics (KHTRF) to C$8 from C$7 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
Questions or Comments about the article? Write to editor@tipranks.com